Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Micardis (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim Official(s) and/or principal investigator(s):
Boehringer Ingelheim, Study Chair, Affiliation: Boehringer Ingelheim
Summary
Practical experience report (PER) investigating the effect of Micardis® on the average 24h
blood pressure of therapy-naive and therapy-experienced patients
Clinical Details
Official title: 24h BP Under Micardis in Daily Practice
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: Efficacy (Change of Systolic Blood Pressure)Efficacy (Change of Diastolic Blood Pressure)
Secondary outcome: Overall Tolerability Scale
Eligibility
Minimum age: 18 Years.
Maximum age: 95 Years.
Gender(s): Both.
Criteria:
Inclusion criteria:
1. Patients who have recently been diagnosed with hypertension
2. Patients whose current blood pressure treatment are inadequate and needs to be
revised are suitable for inclusion.
Exclusion criteria:
None (according to investigator)
Locations and Contacts
Additional Information
Starting date: April 2009
Last updated: February 28, 2014
|
